Latest From kaleo Inc.
Nonprofit Harm Reduction Therapeutics targets an OTC switch of naloxone, an opioid antagonist used to reverse an opioid overdose. It aims to make the product available at low cost in 110,000 retail locations nationwide.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Corporate integrity agreement requires Mylan to have an independent body review its drug classifications and US best price determinations; settlement resolves claims Mylan misclassified EpiPen to underpay rebates. Sanofi acted as whistleblower in case.
Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen
The latest drug development news and highlights from our US FDA Performance Tracker.
- Medical Devices
- Drug Delivery
- Therapeutic Areas
- Immune Disorders
- Intelliject Inc.
- North America
- Parent & Subsidiaries
- kaleo Inc.
- Senior Management
T. Spencer Williamson, IV, Pres. & CEO
Christopher T Schools, CFO
Kristopher D Ford, VP, Bus. Dev.
Eric Edwards, MD, PhD, VP, R&D & CMO
- Contact Info
Phone: (804) 545-6360
111 Virginia St.
Richmond, VA 23219
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.